Editorial
|
|
|
|
|
Unnecessary and dangerous expenditure
|
|
|
|
Marketing Authorisations
|
|
|
|
|
Osteosarcoma: ineffective and harmful
|
|
|
|
|
|
|
|
|
|
A second look in severe persistent asthma: new adverse effects
|
|
|
|
|
|
|
|
|
|
A negative risk-benefit balance in severe persistent asthma
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continue to use pravastatin or simvastatin
|
|
|
|
Adverse Effects
|
|
|
|
|
A neglected adverse effect
|
|
|
|
|
|
|
|
|
|
|
|
Pharmacovigilance signals
|
|
|
|
|
|
|
|
|
|
Marketing authorisation finally suspended in France
|
|
|
|
|
|
|
|
|
|
Pharmacokinetic and pharmacodynamic interactions
|
|
|
|
|
|
|
|
|
|
A review of adverse effects in France
|
|
|
|
Reviews
|
|
|
|
|
A choice largely based on adult data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|